160 related articles for article (PubMed ID: 38485863)
1. Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials.
Egeberg A; Conrad C; Gorecki P; Wegner S; Buyze J; Acciarri L; Thaçi D
Dermatol Ther (Heidelb); 2024 Mar; 14(3):745-758. PubMed ID: 38485863
[TBL] [Abstract][Full Text] [Related]
2. Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.
Kim BS; Jo SJ; Youn S; Reich K; Saadoun C; Chang CL; Yang YW; Huang YH; Tsai TF
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2721-2737. PubMed ID: 37750995
[TBL] [Abstract][Full Text] [Related]
3. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
Armstrong AW; Reich K; Foley P; Han C; Song M; Shen YK; You Y; Papp KA
Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
[TBL] [Abstract][Full Text] [Related]
4. Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.
Tillett W; Egeberg A; Sonkoly E; Gorecki P; Tjärnlund A; Buyze J; Wegner S; McGonagle D
Arthritis Res Ther; 2023 Sep; 25(1):169. PubMed ID: 37715294
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
Foley P; Gordon K; Griffiths CEM; Wasfi Y; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
JAMA Dermatol; 2018 Jun; 154(6):676-683. PubMed ID: 29799960
[TBL] [Abstract][Full Text] [Related]
6. Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.
Puig L; Costanzo A; de Jong EMGJ; Torres T; Warren RB; Wapenaar R; Wegner S; Gorecki P; Gramiccia T; Jazra M; Buyze J; Conrad C
Am J Clin Dermatol; 2024 Mar; 25(2):315-325. PubMed ID: 37804472
[TBL] [Abstract][Full Text] [Related]
7. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
Reich K; Papp KA; Armstrong AW; Wasfi Y; Li S; Shen YK; Randazzo B; Song M; Kimball AB
Br J Dermatol; 2019 May; 180(5):1039-1049. PubMed ID: 30485400
[TBL] [Abstract][Full Text] [Related]
8. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
9. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
10. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
11. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials.
Puig L; Tsai TF; Bhutani T; Uy J; Ramachandran P; Song M; You Y; Gooderham M; Lebwohl M
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1744-1749. PubMed ID: 32289190
[TBL] [Abstract][Full Text] [Related]
12. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
Reich K; Gordon KB; Strober BE; Armstrong AW; Miller M; Shen YK; You Y; Han C; Yang YW; Foley P; Griffiths CEM
Br J Dermatol; 2021 Dec; 185(6):1146-1159. PubMed ID: 34105767
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis:
Youn SW; Yu DY; Kim TY; Kim BS; Lee SC; Lee JH; Choe YB; Lee JH; Choi JH; Roh JY; Jo SJ; Lee ES; Shin MK; Lee MG; Jiang J; Lee Y
J Dermatolog Treat; 2022 Feb; 33(1):535-541. PubMed ID: 32419536
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.
Gordon KB; Blauvelt A; Foley P; Song M; Wasfi Y; Randazzo B; Shen YK; You Y; Griffiths CEM
Br J Dermatol; 2018 Jan; 178(1):132-139. PubMed ID: 28940259
[TBL] [Abstract][Full Text] [Related]
15. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
16. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis.
Puig L
Expert Rev Clin Immunol; 2019 Jun; 15(6):589-597. PubMed ID: 30920855
[TBL] [Abstract][Full Text] [Related]
17. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.
Blauvelt A; Tsai TF; Langley RG; Miller M; Shen YK; You Y; Yang YW; Papp KA; Puig L
J Am Acad Dermatol; 2022 Apr; 86(4):827-834. PubMed ID: 34798201
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
Reich K; Griffiths CEM; Gordon KB; Papp KA; Song M; Randazzo B; Li S; Shen YK; Han C; Kimball AB; Armstrong AW; Foley P; Blauvelt A
J Am Acad Dermatol; 2020 Apr; 82(4):936-945. PubMed ID: 31809827
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations.
Jo SJ; Huang YH; Tsai TF; Kim BS; Reich K; Saadoun C; Chang CL; Yang YW; Youn SW
J Dermatol; 2023 Sep; 50(9):1180-1189. PubMed ID: 37341137
[TBL] [Abstract][Full Text] [Related]
20. Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.
Puig L; Wu JJ; Gooderham MJ; You Y; Shen YK; Randazzo B; Kerdel F
J Dermatolog Treat; 2021 Aug; 32(5):484-491. PubMed ID: 31613178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
